Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
2.

Denosumab: benefits of RANK ligand inhibition in cancer patients.

Lipton A, Jacobs I.

Curr Opin Support Palliat Care. 2011 Sep;5(3):258-64. doi: 10.1097/SPC.0b013e328349731c. Review. Erratum in: Curr Opin Support Palliat Care. 2011 Dec;5(4):369.

PMID:
21826000
3.

[Inhibition of RANK ligand to treat bone metastases].

Body JJ.

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835. Review. French.

PMID:
24158618
4.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
5.

Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.

Sun L, Yu S.

Am J Clin Oncol. 2013 Aug;36(4):399-403. doi: 10.1097/COC.0b013e31824be20e. Review.

PMID:
22772430
6.

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.

Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB.

Pharmacotherapy. 2012 Mar;32(3):274-84. doi: 10.1002/j.1875-9114.2011.01092.x. Epub 2012 Feb 13. Review.

PMID:
22392458
7.

Denosumab in breast cancer.

Lipton A.

Curr Oncol Rep. 2011 Feb;13(1):1-4. doi: 10.1007/s11912-010-0135-y. Review.

PMID:
21053109
8.

Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME.

Cancer Treat Rev. 2013 Feb;39(1):97-104. doi: 10.1016/j.ctrv.2012.07.002. Epub 2012 Aug 13. Review.

9.

New developments for treatment and prevention of bone metastases.

Body JJ.

Curr Opin Oncol. 2011 Jul;23(4):338-42. doi: 10.1097/CCO.0b013e328347918b. Review.

PMID:
21519257
10.

Denosumab and bone metastases. No better than a bisphosphonate.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):204-6. Review.

PMID:
23016249
11.

A comprehensive review of denosumab for bone metastasis in patients with solid tumors.

Gül G, Sendur MA, Aksoy S, Sever AR, Altundag K.

Curr Med Res Opin. 2016;32(1):133-45. doi: 10.1185/03007995.2015.1105795. Epub 2015 Nov 25. Review.

PMID:
26451465
12.

Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.

Scott LJ, Muir VJ.

Drugs. 2011 May 28;71(8):1059-69. doi: 10.2165/11207370-000000000-00000. Review.

PMID:
21668042
13.

Denosumab for the management of bone disease in patients with solid tumors.

Body JJ.

Expert Rev Anticancer Ther. 2012 Mar;12(3):307-22. doi: 10.1586/era.11.204. Epub 2011 Dec 22. Review.

PMID:
22192269
14.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Review.

15.

Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis.

Ford JA, Jones R, Elders A, Mulatero C, Royle P, Sharma P, Stewart F, Todd R, Mowatt G.

Eur J Cancer. 2013 Jan;49(2):416-30. doi: 10.1016/j.ejca.2012.07.016. Epub 2012 Aug 18. Review.

PMID:
22906748
16.

Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.

Gomez-Veiga F, Ponce-Reixa J, Martinez-Breijo S, Planas J, Morote J.

Actas Urol Esp. 2013 May;37(5):292-304. doi: 10.1016/j.acuro.2012.09.001. Epub 2012 Dec 13. Review. English, Spanish.

PMID:
23246105
17.

Effects of bone-targeted agents on cancer progression and mortality.

Coleman R, Gnant M, Morgan G, Clezardin P.

J Natl Cancer Inst. 2012 Jul 18;104(14):1059-67. doi: 10.1093/jnci/djs263. Epub 2012 Jul 2. Review.

PMID:
22752060
18.

Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer.

Kurata T, Nakagawa K.

Jpn J Clin Oncol. 2012 Aug;42(8):663-9. doi: 10.1093/jjco/hys088. Epub 2012 Jun 13. Review.

PMID:
22701037
19.
20.

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.

Cancer Invest. 2002;20 Suppl 2:45-54. Review.

PMID:
12442349

Supplemental Content

Support Center